TY - JOUR
T1 - Surgical treatment of recurrent glioblastoma
T2 - a multicenter perspective from the Italian society of neurosurgery (SINch®) and a systematic review
AU - Panciani, Pier Paolo
AU - Ius, Tamara
AU - Lombardi, Giuseppe
AU - Montemurro, Nicola
AU - Agnoletti, Alessandro
AU - Altieri, Roberto
AU - Barbagallo, Giuseppe M.V.
AU - Buglione, Michela
AU - Catapano, Giuseppe
AU - Cavallo, Luigi Maria
AU - Certo, Francesco
AU - d’Avella, Domenico
AU - Denaro, Luca
AU - Della Pepa, Giuseppe Maria
AU - De Maria, Lucio
AU - Esposito, Vincenzo
AU - Fioravanti, Antonio
AU - Garbossa, Diego
AU - Marton, Elisabetta
AU - Merli, Rossella
AU - Nodari, Giovanni
AU - Olivi, Alessandro
AU - Frati, Alessandro
AU - Pignotti, Fabrizio
AU - Raffa, Giovanni
AU - Raneri, Fabio
AU - Sabatino, Giovanni
AU - Somma, Teresa
AU - Guerrini, Francesco
AU - Spena, Giannantonio
AU - Telera, Stefano
AU - Tomasi, Cesare
AU - Trevisi, Gianluca
AU - Zanin, Luca
AU - Fontanella, Marco Maria
AU - Angileri, Filippo Flavio
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2026.
PY - 2026/12
Y1 - 2026/12
N2 - Given the lack of effective second-line oncotherapy, the role of reoperation and the optimal treatment strategy for recurrent glioblastoma (rGBM) remains controversial. For this reason, we conducted a multicenter retrospective study joined with a systematic literature review to investigate the role of reoperation in patients with rGBM, to identify key factors for the selection of patients that can benefit from reoperation. A retrospective analysis of 236 surgically treated patients with rGBM from 14 different neurosurgical centers between 2012 and 2019 was performed. In addition, a systematic review of the literature was conducted with 87 papers (72 retrospective and 15 prospective) included in the final analysis. In our multicenter cohort, variables significantly relating with a longer post-recurrence survival (PRS) were Karnofsky Performance Status (KPS) at recurrence (p = 0.001), tumor volume at recurrence (p = 0.011), absence of ependymal involvement at recurrence (p = 0.022), MGMT methylation both at first (p = 0.024) and second surgery (p = 0.030), supramaximal contrast-enhancing (CE) resection (RANO Class 1) both at first (p = 0.010) and second surgery (p = 0.002). After a review of the literature, reoperation and a higher preoperative KPS at recurrence were considered statistically significant variables for improved OS in 46/68 studies (68%) and 47/60 studies (78%), respectively. Maximal CE resection at first and second surgery was associated with a longer OS in 37/51 (73%) and 23/34 (68%) studies, respectively. RANO Class 1 resection and a Karnofsky Performance Status ≥ 70 at recurrence appear to be key prdictors to improved post-recurrence survival and preserving quality of life in rGBM patients. Additional factors, including tumor volume at recurrence, ependymal involvement, and MGMT promoter methylation status, should be carefully integrated into the multidisciplinary assessment of suitability for reopration in rGBM patients.
AB - Given the lack of effective second-line oncotherapy, the role of reoperation and the optimal treatment strategy for recurrent glioblastoma (rGBM) remains controversial. For this reason, we conducted a multicenter retrospective study joined with a systematic literature review to investigate the role of reoperation in patients with rGBM, to identify key factors for the selection of patients that can benefit from reoperation. A retrospective analysis of 236 surgically treated patients with rGBM from 14 different neurosurgical centers between 2012 and 2019 was performed. In addition, a systematic review of the literature was conducted with 87 papers (72 retrospective and 15 prospective) included in the final analysis. In our multicenter cohort, variables significantly relating with a longer post-recurrence survival (PRS) were Karnofsky Performance Status (KPS) at recurrence (p = 0.001), tumor volume at recurrence (p = 0.011), absence of ependymal involvement at recurrence (p = 0.022), MGMT methylation both at first (p = 0.024) and second surgery (p = 0.030), supramaximal contrast-enhancing (CE) resection (RANO Class 1) both at first (p = 0.010) and second surgery (p = 0.002). After a review of the literature, reoperation and a higher preoperative KPS at recurrence were considered statistically significant variables for improved OS in 46/68 studies (68%) and 47/60 studies (78%), respectively. Maximal CE resection at first and second surgery was associated with a longer OS in 37/51 (73%) and 23/34 (68%) studies, respectively. RANO Class 1 resection and a Karnofsky Performance Status ≥ 70 at recurrence appear to be key prdictors to improved post-recurrence survival and preserving quality of life in rGBM patients. Additional factors, including tumor volume at recurrence, ependymal involvement, and MGMT promoter methylation status, should be carefully integrated into the multidisciplinary assessment of suitability for reopration in rGBM patients.
KW - Glioblastoma
KW - Multicenter
KW - Recurrence
KW - Recurrent glioblastoma
KW - Second surgery
UR - https://www.scopus.com/pages/publications/105028786174
UR - https://www.scopus.com/pages/publications/105028786174#tab=citedBy
U2 - 10.1007/s10143-025-04104-w
DO - 10.1007/s10143-025-04104-w
M3 - Article
C2 - 41591525
AN - SCOPUS:105028786174
SN - 0344-5607
VL - 49
JO - Neurosurgical Review
JF - Neurosurgical Review
IS - 1
M1 - 163
ER -